Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Sudden cardiac death is a common cause of death in patients with structural heart disease, genetic mutations, or acquired disorders affecting cardiac ion channels. A wide range of platforms exist to model and study disorders associated with sudden cardiac death. Human clinical studies are cumbersome and are thwarted by the extent of investigation that can be performed on human subjects. Animal models are limited by their degree of homology to human cardiac electrophysiology, including ion channel expression. Most commonly used cellular models are cellular transfection models, which are able to mimic the expression of a single-ion channel offering incomplete insight into changes of the action potential profile. Induced pluripotent stem cell-derived cardiomyocytes resemble, but are not identical, adult human cardiomyocytes and provide a new platform for studying arrhythmic disorders leading to sudden cardiac death. A variety of platforms exist to phenotype cellular models, including conventional and automated patch clamp, multielectrode array, and computational modeling. Induced pluripotent stem cell-derived cardiomyocytes have been used to study long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, and other hereditary cardiac disorders. Although induced pluripotent stem cell-derived cardiomyocytes are distinct from adult cardiomyocytes, they provide a robust platform to advance the science and clinical care of sudden cardiac death.

[1]  Joseph C. Wu,et al.  Patient-specific stem cells and cardiovascular drug discovery. , 2013, JAMA.

[2]  R. Guy,et al.  International Conference on Harmonisation , 2014 .

[3]  S. Houser,et al.  Enhanced basal contractility but reduced excitation-contraction coupling efficiency and beta-adrenergic reserve of hearts with increased Cav1.2 activity. , 2010, American journal of physiology. Heart and circulatory physiology.

[4]  T. Okano,et al.  Composite Cell Sheets: A Further Step Toward Safe and Effective Myocardial Regeneration by Cardiac Progenitors Derived From Embryonic Stem Cells , 2010, Circulation.

[5]  S. Szeinbach,et al.  Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 , 2011, Pharmacoepidemiology and drug safety.

[6]  A. Krahn,et al.  Contemporary Reviews in Cardiovascular Medicine Sudden Cardiac Arrest Without Overt Heart Disease , 2011 .

[7]  Michael Glikson,et al.  Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. , 2012, Journal of the American College of Cardiology.

[8]  Chad H. Koonce,et al.  Stem Cells and Their Derivatives: A Renaissance in Cardiovascular Translational Research , 2011, Journal of cardiovascular translational research.

[9]  Dan M Roden,et al.  Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. , 2012, Journal of the American College of Cardiology.

[10]  International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. , 2005, Federal register.

[11]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[12]  W. McKenna,et al.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment , 2013, Canadian Medical Association Journal.

[13]  Mark R Bowlby,et al.  Development of a Novel Automated Ion Channel Recording Method Using “Inside-Out” Whole-Cell Membranes , 2005, Journal of biomolecular screening.

[14]  Erik Willems,et al.  Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery , 2013, Circulation research.

[15]  Hung-Fat Tse,et al.  Electrical Stimulation Promotes Maturation of Cardiomyocytes Derived from Human Embryonic Stem Cells , 2013, Journal of Cardiovascular Translational Research.

[16]  G. Dorn,et al.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. , 2003, The Journal of clinical investigation.

[17]  Euan A. Ashley,et al.  Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.

[18]  Paul B Bennett,et al.  High throughput ion-channel pharmacology: planar-array-based voltage clamp. , 2003, Assay and drug development technologies.

[19]  H. Calkins,et al.  Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.

[20]  P. Coumel,et al.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.

[21]  F. Spinale,et al.  Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. , 2009, Circulation. Heart failure.

[22]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[23]  Tomoaki Inoue,et al.  Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. , 2011, Journal of pharmacological sciences.

[24]  U. Frey,et al.  Microelectronic system for high-resolution mapping of extracellular electric fields applied to brain slices. , 2009, Biosensors & bioelectronics.

[25]  Lawrence Buja,et al.  Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. , 2008, Journal of molecular and cellular cardiology.

[26]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[27]  P. Podrid Proarrhythmia, a serious complication of antiarrhythmic drugs , 1999, Current cardiology reports.

[28]  Michael George,et al.  Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. , 2009, Combinatorial chemistry & high throughput screening.

[29]  Teng Hong Tan,et al.  Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. , 2013, International journal of cardiology.

[30]  D. Roden Repolarization reserve: a moving target. , 2008, Circulation.

[31]  D. Corrado,et al.  Pros and cons of screening for sudden cardiac death in sports , 2013, Heart.

[32]  R. Dolmetsch,et al.  Modeling Timothy Syndrome with iPS Cells , 2013, Journal of Cardiovascular Translational Research.

[33]  Donald M Bers,et al.  Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.

[34]  江頭 徹 Disease characterization using LQTS-specific induced pluripotent stem cells , 2013 .

[35]  S. Kattman,et al.  The generation of the epicardial lineage from human pluripotent stem cells , 2014, Nature Biotechnology.

[36]  H. R. Lu,et al.  Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. , 2013, Stem Cell Research.

[37]  A. Brown,et al.  A history of the role of the hERG channel in cardiac risk assessment. , 2013, Journal of pharmacological and toxicological methods.

[38]  Niels Voigt,et al.  Cardiac safety assays. , 2014, Current opinion in pharmacology.

[39]  Marylyn D. Ritchie,et al.  A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes , 2012, Circulation. Cardiovascular genetics.

[40]  Michael J Ackerman,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[41]  P. Sager,et al.  Electrocardiographic assessment for therapeutic proteins--scientific discussion. , 2010, American heart journal.

[42]  N. McMahon,et al.  Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[44]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[45]  S. Houser,et al.  Cardiac G-Protein–Coupled Receptor Kinase 2 Ablation Induces a Novel Ca2+ Handling Phenotype Resistant to Adverse Alterations and Remodeling After Myocardial Infarction , 2012, Circulation.

[46]  Philip Wong,et al.  Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.

[47]  C. Murry,et al.  Cardiac regeneration using pluripotent stem cells--progression to large animal models. , 2014, Stem cell research.

[48]  J. Dunlop,et al.  A novel method for patch-clamp automation , 2006, Pflügers Archiv.

[49]  Gary R. Mirams,et al.  Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials , 2013, British journal of pharmacology.

[50]  Robert Passier,et al.  Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.

[51]  M. Viitasalo,et al.  Evaluation of QT interval duration and dispersion and proposed clinical criteria in diagnosis of long QT syndrome in patients with a genetically uniform type of LQT1. , 1998, Journal of the American College of Cardiology.

[52]  Barry J Maron,et al.  American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardi , 2008, Journal of the American College of Cardiology.

[53]  Stanley Nattel,et al.  Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs , 2013, The Journal of physiology.

[54]  Robert W. Mills,et al.  Rapid Cellular Phenotyping of Human Pluripotent Stem Cell-Derived Cardiomyocytes using a Genetically Encoded Fluorescent Voltage Sensor , 2014, Stem cell reports.

[55]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[56]  J. Healey,et al.  Systematic Assessment of Patients With Unexplained Cardiac Arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) , 2009, Circulation.

[57]  Andrew J. Sauer,et al.  Contemporary Reviews in Cardiovascular Medicine Clinical and Genetic Determinants of Torsade de Pointes Risk , 2012 .

[58]  Joseph C. Wu,et al.  Induced pluripotent stem cells. , 2015, JAMA.

[59]  G K Isbister,et al.  Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. , 2007, QJM : monthly journal of the Association of Physicians.

[60]  Azra Fatima,et al.  In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells , 2011, Cellular Physiology and Biochemistry.

[61]  Donald M Bers,et al.  Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity , 2013, Circulation.

[62]  José Jalife,et al.  Optical Imaging of Voltage and Calcium in Cardiac Cells & Tissues , 2012, Circulation research.

[63]  G. Keller,et al.  The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. , 2014, Biomaterials.

[64]  J. Brugada,et al.  Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. , 1992, Journal of the American College of Cardiology.

[65]  S. Yamanaka,et al.  The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. , 2009, Biochemical and biophysical research communications.

[66]  P. Burridge,et al.  A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards , 2013, Journal of Cardiovascular Translational Research.

[67]  P. Kirchhof,et al.  Familial Hypertrophic Cardiomyopathy-Linked Mutant Troponin T Causes Stress-Induced Ventricular Tachycardia and Ca2+-Dependent Action Potential Remodeling , 2003, Circulation research.

[68]  R. Papke,et al.  Estimation of both the potency and efficacy of alpha7 nAChR agonists from single-concentration responses. , 2006, Life sciences.

[69]  J. Itskovitz‐Eldor,et al.  Differences between human and mouse embryonic stem cells. , 2004, Developmental biology.

[70]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[71]  Ofer Binah,et al.  Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation , 2012, Journal of cellular and molecular medicine.

[72]  Mathias Jucker,et al.  The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.

[73]  Lior Gepstein,et al.  In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.

[74]  Thomas O'Hara,et al.  Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. , 2012, American journal of physiology. Heart and circulatory physiology.

[75]  R. Nagai,et al.  The mechanism of catecholaminergic polymorphic ventricular tachycardia may be triggered activity due to delayed afterdepolarization. , 1997, European heart journal.

[76]  Gordon Keller,et al.  Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. , 2012, Cell stem cell.

[77]  L. Bailey,et al.  Isolation, Characterization, and Spatial Distribution of Cardiac Progenitor Cells in the Sheep Heart. , 2012, Journal of clinical & experimental cardiology.

[78]  P. Sager,et al.  Moving towards better predictors of drug‐induced torsades de pointes , 2008, British journal of pharmacology.

[79]  L. Rochette,et al.  Postnatal Overfeeding Causes Early Shifts in Gene Expression in the Heart and Long-Term Alterations in Cardiometabolic and Oxidative Parameters , 2013, PloS one.

[80]  H. Calkins,et al.  Identification of a New Modulator of the Intercalated Disc in a Zebrafish Model of Arrhythmogenic Cardiomyopathy , 2014, Science Translational Medicine.

[81]  Arthur A M Wilde,et al.  Cardiac ion channels in health and disease. , 2010, Heart rhythm.

[82]  James A Thomson,et al.  High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.

[83]  Y Rudy,et al.  Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death. , 2001, Cardiovascular research.

[84]  F. Acocella,et al.  Large animal models for cardiac stem cell therapies. , 2011, Theriogenology.

[85]  H. Mistry,et al.  An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. , 2012, American journal of physiology. Heart and circulatory physiology.

[86]  John Sharkey,et al.  Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.

[87]  H. Jneid,et al.  Intracoronary Delivery of Autologous Cardiac Stem Cells Improves Cardiac Function in a Porcine Model of Chronic Ischemic Cardiomyopathy , 2013, Circulation.

[88]  Raatikainen Mj,et al.  New antiarrhythmic drugs for treatment of atrial fibrillation , 2010 .

[89]  Laura Iop,et al.  Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia , 2012, EMBO molecular medicine.

[90]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[91]  S. Chugh,et al.  Sudden cardiac death with apparently normal heart. , 2000, Circulation.

[92]  Paul W. Burridge,et al.  Human Stem Cells for Modeling Heart Disease and for Drug Discovery , 2014, Science Translational Medicine.

[93]  L. Eckardt,et al.  A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. , 2006, European heart journal.

[94]  Y. Li,et al.  β-Adrenergic Stimulation Increases Cav3.1 Activity in Cardiac Myocytes through Protein Kinase A , 2012, PloS one.

[95]  Gary R. Mirams,et al.  Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk , 2011, Cardiovascular research.

[96]  R. Shah,et al.  Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies. , 2005, Novartis Foundation symposium.

[97]  Shinya Yamanaka,et al.  Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[98]  N. Nakatsuji,et al.  Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. , 2013, European heart journal.

[99]  B. Doble,et al.  GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. , 2010, The Journal of clinical investigation.

[100]  Katriina Aalto-Setälä,et al.  Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture , 2011, Disease Models & Mechanisms.

[101]  Clemens Möller,et al.  Automated planar patch-clamp. , 2013, Methods in molecular biology.

[102]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, The New England journal of medicine.

[103]  A. Wilde,et al.  SCN5A overlap syndromes: no end to disease complexity? , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[104]  Kapil Kumar,et al.  Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[105]  N. Weissman,et al.  Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin , 2000, The Journal of physiology.

[106]  A. Jervell,et al.  Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death , 1957 .

[107]  Euan A Ashley,et al.  Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.

[108]  D. Dobrev,et al.  New directions in antiarrhythmic drug therapy for atrial fibrillation. , 2013, Future cardiology.

[109]  Jürgen Hescheler,et al.  Organotypic slice culture from human adult ventricular myocardium. , 2012, Cardiovascular research.

[110]  Michael Fejtl,et al.  The roboocyte: automated cDNA/mRNA injection and subsequent TEVC recording on Xenopus oocytes in 96-well microtiter plates. , 2003, Receptors & channels.

[111]  T. Smart,et al.  HEK293 cell line: a vehicle for the expression of recombinant proteins. , 2005, Journal of pharmacological and toxicological methods.

[112]  Divya Rajamohan,et al.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation , 2011, European Heart Journal.

[113]  M. Kay,et al.  Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. , 2014, Journal of the American College of Cardiology.

[114]  C. Tracy,et al.  HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.

[115]  C. Mummery,et al.  Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. , 2011, Trends in molecular medicine.

[116]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[117]  P Ducimetière,et al.  Predicting sudden death in the population: the Paris Prospective Study I. , 1999, Circulation.

[118]  D. Dobrev,et al.  Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. , 2005, The Journal of thoracic and cardiovascular surgery.

[119]  Feng Chen,et al.  Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. , 2014, Cell stem cell.

[120]  Ferran Sanz,et al.  A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity , 2011, J. Chem. Inf. Model..

[121]  International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. , 2005, Federal register.

[122]  Gary Gintant,et al.  Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. , 2014, American heart journal.

[123]  J J Heger,et al.  Sudden cardiac death. , 1998, Circulation.

[124]  A. Sandoval,et al.  Whole-cell patch-clamp recording of recombinant voltage-sensitive Ca2+ channels heterologously expressed in HEK-293 cells. , 2014, Cold Spring Harbor protocols.

[125]  Udo Kraushaar,et al.  Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals , 2010, Expert opinion on drug metabolism & toxicology.

[126]  M. Spira,et al.  Multi-electrode array technologies for neuroscience and cardiology. , 2013, Nature nanotechnology.

[127]  C. Mummery,et al.  Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias , 2012, Front. Physio..

[128]  C. Mummery,et al.  Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease , 2012, Circulation.

[129]  D. Roden Long QT syndrome: reduced repolarization reserve and the genetic link , 2006, Journal of internal medicine.

[130]  Gene Kim,et al.  MicroRNA regulation of cardiac conduction and arrhythmias. , 2013, Translational research : the journal of laboratory and clinical medicine.

[131]  Stanley Nattel,et al.  Molecular basis of species-specific expression of repolarizing K+ currents in the heart. , 2003, American journal of physiology. Heart and circulatory physiology.

[132]  S. Schiffmann,et al.  Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich’s ataxia , 2012, Disease Models & Mechanisms.

[133]  E. Behr,et al.  Drug-induced arrhythmia: pharmacogenomic prescribing? , 2013, European heart journal.

[134]  O. Abilez,et al.  Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells. , 2014, Journal of the American College of Cardiology.

[135]  Xu Xiaoping,et al.  Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype. , 2013, American journal of physiology. Heart and circulatory physiology.